A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy
Latest Information Update: 18 May 2022
At a glance
- Drugs Panobinostat (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Hodgkin's disease; Multiple myeloma; Mycosis fungoides; Sezary syndrome; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms VEG-VCA1
- 03 May 2022 Status changed from active, no longer recruiting to completed.
- 14 Aug 2012 New trial record